CG Oncology Stock Forecast

Stock Price Forecast

According to 15 analysts polled by S&P Global, CG Oncology stock has a consensus rating of "Strong Buy" and an average price target of $91.08. The average 1-year stock price forecast is 18.83% higher than the current stock price, while the lowest is $79 (+3.07%) and the highest is $108 (+40.90%).

Price Target: $91.08 (+18.83%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$79	$91.08	$90	$108
Change	+3.07%	+18.83%	+17.42%	+40.90%

Analyst Ratings

The average analyst rating for CG Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Mar '26	Apr '26	May '26	Jun '26	Jul '26	Aug '26
Strong Buy	11	11	11	11	10	10
Buy	4	4	4	4	4	4
Hold	0	0	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	15	15	16	16	15	15

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Sam Slutsky LifeSci Capital	LifeSci Capital	Buy Maintains $108	Buy	Maintains	$108	+40.90%	Aug 7, 2026
Joshua Schimmer Cantor Fitzgerald	Cantor Fitzgerald	Buy Reiterates $105	Buy	Reiterates	$105	+36.99%	Aug 7, 2026
Gregory Renza Truist Financial	Truist Financial	Buy Reiterates $82 → $85	Buy	Reiterates	$82 → $85	+10.89%	Aug 7, 2026
Kelsey Goodwin Piper Sandler	Piper Sandler	Buy Reiterates $82 → $85	Buy	Reiterates	$82 → $85	+10.89%	Aug 7, 2026
Leonid Timashev RBC Capital	RBC Capital	Buy Maintains $81 → $79	Buy	Maintains	$81 → $79	+3.07%	Aug 7, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

3.31M

from 4.04M

-18.12%

from 4.04M

Revenue Next Year

91.54M

from 3.31M

2,667.13%

from 3.31M

EPS This Year

-3.22

from -2.08

EPS Next Year

-2.90

from -3.22

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	10.36M	191.00K	204.00K	1.14M	4.04M	3.31M
Revenue Growth	-	-98.16%	6.81%	458.33%	254.70%	-18.12%
Operating Income	-12.61M	-35.25M	-55.45M	-114.67M	-190.77M	-315.37M
Net Income	-12.84M	-35.44M	-48.61M	-88.04M	-161.00M	-290.60M
EPS	-	-	-	-	-2.08	-3.22
Free Cash Flow	-	-16.95M	-28.07M	-59.08M	-87.62M	-281.58M
No. Analysts	-	-	-	-	-	12

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	4.6M
Avg	3.3M
Low	2.2M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	15.0%
Avg	-18.1%
Low	-45.5%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-2.79
Avg	-3.22
Low	-3.60

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-